| Patents for A61P 19 - Drugs for skeletal disorders (81,981) |
|---|
| 02/19/2004 | WO2004014430A1 Compositions of a cyclooxygenase-2 selective inhibitor and a carbonic anhydrase inhibitor for the treatment of neoplasia |
| 02/19/2004 | WO2004014415A1 Growth hormone releasing peptides |
| 02/19/2004 | WO2004014406A1 Use of fermented wheat germ extract as anti-inflammatory agent |
| 02/19/2004 | WO2004014399A1 Process for preparing a sterile high molecular weight hyaluronic acid formulation |
| 02/19/2004 | WO2004014395A1 Female hormone-containing patch |
| 02/19/2004 | WO2004014387A1 COMBINATION THERAPY WITH p38 MAP KINASE INHIBITORS AND THEIR PHARMACEUTICAL COMPOSITIONS |
| 02/19/2004 | WO2004014379A1 Isoquinoline derivatives as matrix metalloproteinase inhibitors |
| 02/19/2004 | WO2004014378A1 3-isoquinolinone derivatives as matrix metalloproteinase inhiitors |
| 02/19/2004 | WO2004014374A1 Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them |
| 02/19/2004 | WO2004014372A1 Acylated, heteroaryl-condensed cycloalkenylamines and their use as pharmaceuticals |
| 02/19/2004 | WO2004014369A1 Acylamino-substituted heteroaromatic compounds and their use as pharmaceuticals |
| 02/19/2004 | WO2004014352A2 Methods for treating carbonic anhydrase mediated disorders |
| 02/19/2004 | WO2004014304A2 Electrospun amorphous pharmaceutical compositions |
| 02/19/2004 | WO2004007481A3 Substituted amine derivatives and methods of use in the treatment of angiogenesis relates disorders |
| 02/19/2004 | WO2004007430A3 Benzamide or phenylacetamide derivatives useful as thyroid receptor ligands |
| 02/19/2004 | WO2004000312A3 Medicament for the treatment of diseases requiring inhibition or a reduction in the activity of ph value-regulating bicarbonate transporter proteins |
| 02/19/2004 | WO2003104473A3 Galactosyl isomalt, method for production and use thereof |
| 02/19/2004 | WO2003097852A3 Assay for identifying inhibitors of fc gamma riii signaling |
| 02/19/2004 | WO2003070188A3 Method of treating trx mediated diseases |
| 02/19/2004 | WO2003065987A3 Granzyme b inhibitors |
| 02/19/2004 | WO2003057149B1 4-substituted fused heteropyrimidines and fused hetero-4-pyrimidones |
| 02/19/2004 | WO2003045974A3 Methods and compositions for derepression of iap-inhibited caspase |
| 02/19/2004 | WO2003045398A8 Methods of making and pharmaceutical formulations comprising 7alpha, 11beta-dimethy-17beta-hydroxyestra-4, 14-dien-3-one and 17 esters thereof |
| 02/19/2004 | WO2003034028A3 Methods for identifying and using modulators of estrogen related receptor gamma |
| 02/19/2004 | WO2003032907A3 High-concentration protein formulations and method of manufacture |
| 02/19/2004 | WO2003027234A9 Small organic molecule regulators of cell proliferation |
| 02/19/2004 | WO2003025014A3 Use of peptides comprising post-translational modifications in the treatment of autoimmune pathologies |
| 02/19/2004 | WO2003014731A3 The natural ligand for orphan g protein coupled receptor gpr86 and methods of use |
| 02/19/2004 | WO2002088184A9 A molecular marker |
| 02/19/2004 | WO2002070023A3 Compositions comprising bone marrow cells together with demineralized and/or mineralized bone matrix and uses thereof in the induction of bone and cartilage formation |
| 02/19/2004 | WO2002064160A3 Pharmaceutical compositions which inhibit vascular proliferation and method of use thereof |
| 02/19/2004 | WO2002048337A3 Secreted human proteins |
| 02/19/2004 | WO2002024214A3 Use of glp -2 in combination with another therapeutic agent in bone-related and nutrition-related disorders |
| 02/19/2004 | US20040034229 3,4-Di-substituted maleimide compounds as CXC chemokine receptor antagonists |
| 02/19/2004 | US20040034218 Farnesyl transferase inhibiting benzoheterocyclic derivatives |
| 02/19/2004 | US20040034090 Such as (7-chloro-2-methyl-1-(3-(methylsulphanyl)propyl)-1H-indol-3-yl)(2,3-dichloro-phenyl)methanone; cannabinoid receptors (cb2); G proteins coupled receptors |
| 02/19/2004 | US20040034086 For treatment of diseases characterized by connective tissue breakdown, cartilage damage, and inflammation/pain such as arthritis, heart failure, multiple sclerosis, atherosclerosis, and osteoporosis |
| 02/19/2004 | US20040034085 For treatment of cartilage damage, inflammation, arthritis, and pain; treating diseases such as rheumatoid arthritis/osteoarthritis, heart failure, multiple sclerosis, atherosclerosis, and osteoporosis |
| 02/19/2004 | US20040034084 Side effect reduction; for treatment of AIDS, cancer and arthritis |
| 02/19/2004 | US20040034081 Estrogen receptor modulators |
| 02/19/2004 | US20040034073 Analgesic agents, modulating the activity of a cannabinoid receptor, treating hypertension, inflammation, pain, autoimmune diseases, allergic diseases, glaucoma, multiple sclerosis, Huntington's chorea, spinal chord injury |
| 02/19/2004 | US20040034052 Antitumor agents |
| 02/19/2004 | US20040034046 Quinazoline derivatives |
| 02/19/2004 | US20040034017 4-fluoroalkyl-2h-benzopyrans anti-estogenic activity |
| 02/19/2004 | US20040034005 Administering to a patient suffering from psychological disoders a (1,4)diazocino(7,7,1-hi)inodle derivative as 5HT2c agonist or partial agonist |
| 02/19/2004 | US20040033995 Nitrogen compounds, stereoisomers and/or racemic mixtures used as enzyme inhibitors for prophylaxis of inflammatory diseases |
| 02/19/2004 | US20040033952 Modified mature insulin variants and composition containing same |
| 02/19/2004 | US20040033951 Modified mature insulin variants and composition containing same |
| 02/19/2004 | US20040033949 Use of VEGF for treating bone defects |
| 02/19/2004 | US20040033933 Process for preparing composition comprising medicinal herb extract for preventing and curing arthritis and composition thereof |
| 02/19/2004 | US20040033535 Antibodies to OPGL |
| 02/19/2004 | US20040033511 Site-specific antibody-mediated activation of proapoptotic cytokines: AMAIZEe (antibody-mediated apoptosis inducing cytokines) |
| 02/19/2004 | US20040033231 First domain comprising a PP14 polypeptide sequence and a second domain comprising a polypeptide sequence of the Fc region of an immunoglobulin protein; treatment of immune system diseases and disorders |
| 02/19/2004 | US20040033221 Method for the treatment of chemonucleolysis |
| 02/19/2004 | US20040033218 Extracellular matrix (ecm); cell and genetic therapy |
| 02/19/2004 | US20040033212 Isolated population of superficial zone chondroprogenitor cells; replacement of damaged cartilage |
| 02/19/2004 | US20040033211 Antigen arrays for treatment of bone disease |
| 02/19/2004 | DE10237423A1 Treating immunological (or related) diseases, e.g. inflammatory bowel disease, rheumatoid arthritis or psoriasis, comprises administration of 3-methylene-2-indolinone derivative or quinazoline compound |
| 02/19/2004 | CA2497658A1 Chromone derivatives as matrix metalloproteinase inhibitors |
| 02/19/2004 | CA2497448A1 Combination therapy with p38 map kinase inhibitors and their pharmaceutical compositions |
| 02/19/2004 | CA2495518A1 Bicyclic heteroaromatic compounds as kinase inhibitors |
| 02/19/2004 | CA2495516A1 Compositions of a cyclooxygenase-2 selective inhibitor and a carbonic anhydrase inhibitor for the treatment of neoplasia |
| 02/19/2004 | CA2495502A1 Methods for treating carbonic anhydrase mediated disorders |
| 02/19/2004 | CA2495067A1 Mcp-1 receptor antagonists and method of use thereof |
| 02/19/2004 | CA2494865A1 Electrospun amorphous pharmaceutical compositions |
| 02/19/2004 | CA2494827A1 Cannabinoid receptor ligands |
| 02/19/2004 | CA2494744A1 Use of fermented wheat germ extract as anti-inflammatory agent |
| 02/19/2004 | CA2494298A1 Acylamino-substituted heteroaromatic compounds and their use as pharmaceuticals |
| 02/19/2004 | CA2494026A1 Phosphodiesterase 4 inhibitors |
| 02/19/2004 | CA2494014A1 Monocyclic derivatives as matrix metalloproteinase inhibitors |
| 02/19/2004 | CA2493660A1 Process for preparing quinolin antibiotic intermediates |
| 02/19/2004 | CA2493625A1 Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them |
| 02/19/2004 | CA2492019A1 Isoquinoline derivatives as matrix metalloproteinase inhibitors |
| 02/18/2004 | EP1389619A1 Pkb-3564 substance with neovascularization inhibitory activity |
| 02/18/2004 | EP1389618A1 Pyrazolo 1,5-a]pyridines and medicines containing the same |
| 02/18/2004 | EP1389616A1 Novel benzylpiperidine compound |
| 02/18/2004 | EP1389468A1 Compositions for promoting healing of bone fracture |
| 02/18/2004 | EP1389467A1 Therapeutic compositions for repairing chondropathy |
| 02/18/2004 | EP1389233A1 Anti-rank ligand monoclonal antibodies useful in treatment of rank ligand mediated disorders |
| 02/18/2004 | EP1389206A2 Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases |
| 02/18/2004 | EP1389205A1 Quinazoline and quinazoline-like compounds for the treatment of integrin-mediated disorders |
| 02/18/2004 | EP1389204A1 Novel sulfonamide derivatives, intermediate thereof, its preparation methods, and pharmaceutical composition comprising the same |
| 02/18/2004 | EP1389201A1 N-oxide anthranylamide derivatives and their use as medicaments |
| 02/18/2004 | EP1389181A2 Antioxidant nitroxides and nitrones as therapeutic agents |
| 02/18/2004 | EP1389137A2 Compositions for protein delivery via the pulmonary route |
| 02/18/2004 | EP1389124A1 Palliative effects of morinda citrifolia oil and juice |
| 02/18/2004 | EP1389120A2 Identifying parasitic fungi of the organism, and treatment thereof |
| 02/18/2004 | EP1389112A2 Use of radical scavenging compounds for treatment and prevention of no-dependent microcirculation disorders |
| 02/18/2004 | EP1389110A2 Inhibitors of macrophage migration inhibitory factor and methods for identifying the same |
| 02/18/2004 | EP1389103A2 Synthesis and evaluation of novel phthalimide mimics as anti-angiogenic agents |
| 02/18/2004 | EP1389044A1 Ppar-alpha-gamma ligands or agonists for the treatment of inflammation |
| 02/18/2004 | EP1233786B1 Product comprising at least a no synthase inhibiting substance associated with at least a phospholipase a2 inhibiting substance for the preparation of a medicament |
| 02/18/2004 | EP1216238B1 Carboxylic acids and acylsulfonamides, compositions containing such compounds and methods of treatment |
| 02/18/2004 | EP1183252B1 pharmaceutically active compounds |
| 02/18/2004 | EP1178958B1 N-cyanomethyl amides as protease inhibitors |
| 02/18/2004 | EP1119568B1 4,5-dihydro-isoxazole derivatives and their pharmaceutical use |
| 02/18/2004 | EP0980351B1 Benzylamine and phenylethylamine derivatives, processes for preparing the same and their use as medicaments |
| 02/18/2004 | CN1476448A Aryl or heteroaryl fused imidazole compounds as anti-inflammatory and analgesic agents |
| 02/18/2004 | CN1476447A Aminothiazoles and their use as adenosine receptor antagonists |
| 02/18/2004 | CN1476442A Pyridine derivatives with IKB-kinase (IKK-beta) INhibiting activity |